Kiora Q2 FY26 net loss narrows to $2.1 million

Reuters2026/08/07 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kiora Pharmaceuticals posted a Q2 net loss of USD 2.08 million, narrowing from USD 2.15 million a year earlier; loss per share improved to USD 0.34 from USD 0.54.
R&D expense fell to USD 2.08 million from USD 2.59 million; collaboration credits declined to USD 1.34 million from USD 1.69 million.
Cash and short-term investments rose to about USD 16.8 million at June 30 from USD 13.9 million at March 31, extending expected runway into late 2028.
Private placement secured for up to USD 24 million in gross proceeds, including USD 5 million upfront; remaining proceeds tied to milestone-based warrant exercises.
ABACUS-2 advanced into a 100 µg dose cohort with topline data expected in Q3 2027; KLARITY higher-dose enrollment continues with initial data expected late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608070700NEWSFILECNPR____20260807_308423_1) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kiora Q2 FY26 net loss narrows to $2.1 million

You may also like

Crypto prices